---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-026692"
form_type: "8-K"
ticker: "SANA"
cik: "0001770121"
company_name: "Sana Biotechnology, Inc."
filed_at: "2024-02-07T23:59:59+00:00"
generated_at: "2026-06-06T07:09:27.947020+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Sana reports SC291 ARDENT interim data with responses and immune evasion; cash $205.4M

## Summary
- Preliminary cash, cash equivalents and marketable securities as of Jan 2, 2024: approximately $205.4 million.
- ARDENT interim: 4 evaluable patients; 3 partial responses including ongoing complete responses; no DLTs, GVHD, or CRS/ICANS.
- HIP-edited CAR T cells evaded innate and adaptive immune responses in all 4 evaluable patients; non-HIP cells were recognized.
- IND cleared for GLEAM (lupus/vasculitis) and VIVID (CD22 CAR T) trials; data expected in 2024.
- Preclinical: HIP primary islets in diabetic NHP achieved insulin independence for 6 months without immunosuppression; IST of UP421 authorized.

## SEC filing metadata
- accession: 0001193125-24-026692
- form_type: 8-K
- ticker: SANA
- cik: 0001770121
- company_name: Sana Biotechnology, Inc.
- filed_at: 2024-02-07T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1770121/000119312524026692/0001193125-24-026692-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1770121/000119312524026692/d180813d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-026692
- JSON: https://secwatch.observer/filing/0001193125-24-026692.json
- Plain text: https://secwatch.observer/filing/0001193125-24-026692.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.